Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Nephrology Boards: Glomerular Diseases > Paraprotein-Related Disorders > Flashcards

Paraprotein-Related Disorders Flashcards

1
Q

Paraprotein-Related Disorders

Epidemiology

A

Multiple Myeloma and the Kidney

Kidney involvement is common:

40% of patients present with SCr > 1.5 mg/dL.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Paraprotein-Related Disorders

Epidemiology

A

Survival is associated with kidney function following treatment of multiple myeloma.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Paraprotein-Related Disorders

Renal Manifestations (Combination of Lesions May Be Present in Same Patient)

Tubular involvement:

A

Light-chain (Bence Jones) cast nephropathy a.k.a. “myeloma kidney”:

Most common renal presentation (40% to 60%) in association with elevated SCr

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Paraprotein-Related Disorders

Renal Manifestations (Combination of Lesions May Be Present in Same Patient)

Tubular involvement:

A

Pathogenesis: acute or chronic kidney injury due to filtration of toxic light chains leading to tubular injury and intratubular cast formation and obstruction.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Paraprotein-Related Disorders

Renal Manifestations (Combination of Lesions May Be Present in Same Patient)

Tubular involvement:

A

Histopathology: LM: Light chain casts which are angulated, fractured or coarsely granular staining orange on Masson trichrome and PAS negative in distal tubules. Casts are often surrounded or engulfed by multinucleated giant cells. IF: casts stain strongly for the abnormal light chain, with minimal staining for other immune reactants.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Paraprotein-Related Disorders

Renal Manifestations (Combination of Lesions May Be Present in Same Patient)

Tubular involvement:

A

Associated with “proteinuria mismatch.” Proteinuria from cast nephropathy arises from the large amount of filtered free light chains (FLC) “Bence Jones protein,” which, unlike albumin, are not well detected by the routine urinalysis dipstick. That is, while a urine dipstick may indicate “trace” or “1+” proteinuria, the actual quantification of proteinuria from a 24-hour urine collection or uPCR would be equivalent to “≥3+” proteinuria.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Paraprotein-Related Disorders

Renal Manifestations (Combination of Lesions May Be Present in Same Patient)

Tubular involvement:

A

Proteinuria mismatch may also be unmasked by the addition of sulfosalicylic acid (SSA) to the urine sample because SSA precipitates all proteins including all albumin as well as light chains.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Paraprotein-Related Disorders

Renal Manifestations (Combination of Lesions May Be Present in Same Patient)

Tubular involvement:

A

Fanconi syndrome: proximal tubular injury due to the reabsorption and accumulation of crystallized nondegradable toxic variable domain fragments of the filtered light chains. Patients may present with various proximal tubular transport defects including proximal renal tubular acidosis, phosphate wasting, uricosuria (hence hypouricemia), euglycemic glucosuria, and aminoaciduria.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Paraprotein-Related Disorders

Renal Manifestations (Combination of Lesions May Be Present in Same Patient)

Tubular involvement:

A

Histopathology: LM: Crystalline inclusions (stain as light blue on H&E) with tubular damage may be seen in proximal tubular cells. EM: proximal tubular cells are filled with electron-dense light-chain crystals with needle, rod, rhomboid, or rectangular shapes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Paraprotein-Related Disorders

Renal Manifestations (Combination of Lesions May Be Present in Same Patient)

Tubular involvement:

A

Distal tubular dysfunction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Paraprotein-Related Disorders

Renal Manifestations (Combination of Lesions May Be Present in Same Patient)

Interstitial involvement:

A

Plasma cell infiltration

Interstitial nephritis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Paraprotein-Related Disorders

Glomerular involvement:

Primary amyloidosis (20% to 30%), (AL, ALH, or rarely AH)

A

Two-third of cases are from λ-light chains

Light chains are partially metabolized in macrophages then secreted. The metabolized fragments may precipitate into granular deposits and β-pleated fibrils as “amyloid,” which is Congo-red positive.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Paraprotein-Related Disorders

Glomerular involvement:

Primary amyloidosis (20% to 30%), (AL, ALH, or rarely AH)

A

Amyloid depositions within the kidney leading to extensive mesangial and GBM injury can manifest as significant albuminuria and nephrotic range proteinuria. Since routine urinalysis with a dipstick can detect albuminuria well, “proteinuria mismatch” is not characteristic of renal amyloidosis in contrast to that seen in myeloma kidney/cast nephropathy.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Paraprotein-Related Disorders

Glomerular involvement:

Primary amyloidosis (20% to 30%), (AL, ALH, or rarely AH)

A

In the case of predominant interstitial and vascular involvement, progressive kidney injury occurs but with minimal proteinuria.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Paraprotein-Related Disorders

Glomerular involvement:

Monoconal Immunoglobulin Deposition Disease (MIDD) involves the deposition of monoclonal light chain (80%), and less commonly heavy chain (10%), or both (10%) in the mesangium and tubular and GBMs.

A

Monoclonal κ-light chain is most common with MIDD (two-third of cases)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Paraprotein-Related Disorders

Glomerular involvement:

Monoconal Immunoglobulin Deposition Disease (MIDD) involves the deposition of monoclonal light chain (80%), and less commonly heavy chain (10%), or both (10%) in the mesangium and tubular and GBMs.

A

Same pathogenesis as amyloidosis, but light chain fragments in this case do not form β-pleated fibrils and are Congo red negative.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Paraprotein-Related Disorders

Glomerular involvement:

Monoconal Immunoglobulin Deposition Disease (MIDD) involves the deposition of monoclonal light chain (80%), and less commonly heavy chain (10%), or both (10%) in the mesangium and tubular and GBMs.

A

As GBM is affected and significant albuminuria can occur, MIDD does not present with proteinuria mismatch.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Paraprotein-Related Disorders

Glomerular involvement:

Others: MPGN, monoclonal cryoglobulinemia, proliferative GN with monoclonal Ig deposits (PGNMID), intraglomerular IgM deposits with resultant thrombi formation (Waldenstroms macroglobulinemia), immunotactoid GN, fibrillary GN, and rarely MCD.

A

MPGN associated with monoclonal gammopathy often presents with both IgG and C3 deposits, or less commonly, IgM and C3 deposits. Rarely, some monoclonal Ig proteins and/or their fragments can inhibit complement alternative pathway regulatory proteins (CfH or C3Bb) and induce a “complement-only” form of GN.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Paraprotein-Related Disorders

Glomerular involvement:

Others: MPGN, monoclonal cryoglobulinemia, proliferative GN with monoclonal Ig deposits (PGNMID), intraglomerular IgM deposits with resultant thrombi formation (Waldenstroms macroglobulinemia), immunotactoid GN, fibrillary GN, and rarely MCD.

A

Older patients with C3GN should therefore also be evaluated for a monoclonal gammopathy.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Paraprotein-Related Disorders

Glomerular involvement:

Others: MPGN, monoclonal cryoglobulinemia, proliferative GN with monoclonal Ig deposits (PGNMID), intraglomerular IgM deposits with resultant thrombi formation (Waldenstroms macroglobulinemia), immunotactoid GN, fibrillary GN, and rarely MCD.

A

PGNMID and immunotactoid GN may present with hypocomplementemia in 1/3 of cases.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Paraprotein-Related Disorders

Glomerular involvement:

Others: MPGN, monoclonal cryoglobulinemia, proliferative GN with monoclonal Ig deposits (PGNMID), intraglomerular IgM deposits with resultant thrombi formation (Waldenstroms macroglobulinemia), immunotactoid GN, fibrillary GN, and rarely MCD.

A

Immunotactoid GN is much more commonly associated with monoclonal gammopathy/lymphoproliferative disease than fibrillary GN.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Paraprotein-Related Disorders

Glomerular involvement:

Others: MPGN, monoclonal cryoglobulinemia, proliferative GN with monoclonal Ig deposits (PGNMID), intraglomerular IgM deposits with resultant thrombi formation (Waldenstroms macroglobulinemia), immunotactoid GN, fibrillary GN, and rarely MCD.

A

Fiber size difference: Amyloid fibrils are smallest with diameter 10 nm, fibrillary fibrils are 15 to 25 nm, immunotactoid microtubules are 30 to 50 nm and cryoglobulin microtubules are 20 to 30 nm.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Paraprotein-Related Disorders

Glomerular involvement:

Others: MPGN, monoclonal cryoglobulinemia, proliferative GN with monoclonal Ig deposits (PGNMID), intraglomerular IgM deposits with resultant thrombi formation (Waldenstroms macroglobulinemia), immunotactoid GN, fibrillary GN, and rarely MCD.

A

Electron microscopy: amyloidosis, fibrillary immunotactoid and cyroglobulin fibrils/microtubules

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Paraprotein-Related Disorders

Other complications associated with paraproteinemia:

A

Hypercalcemia: nephrocalcinosis, interstitial nephritis, reduced renal perfusion due to hypercalcemia induced vasoconstriction, intratubular calcium salt precipitations.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Paraprotein-Related Disorders

Other complications associated with paraproteinemia:

A

Hyperuricemia: acute uric acid nephropathy, interstitial nephritis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Paraprotein-Related Disorders

Other complications associated with paraproteinemia:

A

Light-chain deposition in muscle leading to rhabdomyolysis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Paraprotein-Related Disorders

Other complications associated with paraproteinemia:

Hyperviscosity syndrome:

A

Associated with excessive formation of abnormal polymers of IgA or IgG3 or κ-light chains

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Paraprotein-Related Disorders

Other complications associated with paraproteinemia:

Hyperviscosity syndrome:

A

Clinical manifestations: blurred vision, neurologic symptoms, confusion, oral/nasal bleeding, heart failure, kidney injury/acute tubular necrosis

29
Q

Paraprotein-Related Disorders

Other complications associated with paraproteinemia:

Hyperviscosity syndrome:

A

Treatment: plasmapheresis if obvious symptoms regardless of serum viscosity index. Serum viscosity index may not correlate well with symptoms.

30
Q

Paraprotein-Related Disorders

Other complications associated with paraproteinemia:

Volume depletion:

A

Hypercalcemia-induced nephrogenic diabetes insipidus

Reduced oral intake

Cardiomyopathy (e.g., amyloid involvement)

31
Q

Paraprotein-Related Disorders

Other complications associated with paraproteinemia:

Treatment related:

A

Drugs (NSAIDS), antibiotics

Use of intravenous contrast dye with computed tomography

32
Q

Paraprotein-Related Disorders

Other complications associated with paraproteinemia:

Treatment related:

A

Bisphosphonates (zolendronate: acute tubular necrosis; pamidronate, zolendronate: FSGS)

33
Q

Paraprotein-Related Disorders

Diagnosis

Nonspecific clues suggesting the possibility of paraproteinemia, multiple myeloma:

Urine studies:

A

Routine urinalysis is typically “bland.”

Urine-free light chains > 1,500 mg/L, proteinuria mismatch, and low percentage of albuminuria compared to total proteinuria indicate myeloma cast nephropathy.

Glucosuria in the absence of hyperglycemia; phosphaturia; renal tubular acidosis

34
Q

Paraprotein-Related Disorders

Diagnosis

Nonspecific clues suggesting the possibility of paraproteinemia, multiple myeloma:

Chemistries:

A

Low to positive serum anion gap

Hypercalcemia

35
Q

Paraprotein-Related Disorders

Diagnosis

Nonspecific clues suggesting the possibility of paraproteinemia, multiple myeloma:

Chemistries:

A

Hyperphosphatemia out of proportion to degree of kidney failure if high levels of serum FLC as they may give falsely high phosphate levels

36
Q

Paraprotein-Related Disorders

Diagnosis

Nonspecific clues suggesting the possibility of paraproteinemia, multiple myeloma:

Chemistries:

A

High serum total protein to albumin ratio

Low complements in PGNMID and immunotactoid GN

37
Q

Paraprotein-Related Disorders

Diagnosis

Testing options for monoclonal gammopathy:

A

Serum (or urine) protein electrophoresis (SPEP or UPEP): SPEP separates serum proteins into five general regions in the order of albumin, α1, α2, β, and γ based on their charge and size.

38
Q

Paraprotein-Related Disorders

Diagnosis

Testing options for monoclonal gammopathy:

A

The various immunoglobulin classes (IgG, IgA, IgM, IgD, and IgE) are usually of γ mobility, but they may also be found in the β-γ and β regions, and occasionally extend into the α2-globulin area.

39
Q

Paraprotein-Related Disorders

Diagnosis

Testing options for monoclonal gammopathy:

A

An “M”-spike indicates the presence of a “M”onoclonal protein. Each M-protein consists of two heavy polypeptide chains of the same class: γ (IgG: IgG1-IgG4), α (IgA: IgA1, IgA2), µ (IgM), δ (IgD), ε (IgE).

40
Q

Paraprotein-Related Disorders

Diagnosis

Testing options for monoclonal gammopathy:

A

The paired heavy chains are associated with two light chains of the same type (κ or λ), not both.

41
Q

Paraprotein-Related Disorders

Diagnosis

Testing options for monoclonal gammopathy:

A

“Polyclonal gamma globulin” on SPEP does not indicate a monoclonal gammopathy, but a polyclonal immunoglobulin production in response to various conditions including liver disease, connective tissue, nonspecific inflammatory disorders.

42
Q

Paraprotein-Related Disorders

Diagnosis

Testing options for monoclonal gammopathy:

A

SPEP is a useful screening procedure but it may miss a small M-protein spike or falsely identify a polyclonal increase in Ig or non-Ig as an M-protein spike. Identification of the actual makeup of the M-protein requires immunofixation.

43
Q

Paraprotein-Related Disorders

Diagnosis

Testing options for monoclonal gammopathy:

A

In serum (or urine) protein immunofixation electrophoresis (IFE), antibodies directed against the heavy and light chains (anti-γ, anti-mu, anti-α [IgG, M, A] and anti-κ and anti-λ) are added following the initial electrophoresis procedure to identify overproduction of any corresponding chain.

44
Q

Paraprotein-Related Disorders

Diagnosis

Testing options for monoclonal gammopathy:

A

Direct assay for serum-free light chain (Bence Jones) is more sensitive in establishing the diagnosis of monoclonal gammopathy than either SPEP or IFE. However, it must be noted that the quantity of both κ and λ light chains may be increased with poor kidney function due to reduced renal excretion.

45
Q

Paraprotein-Related Disorders

Diagnosis

Testing options for monoclonal gammopathy:

A

The abnormal ratio of κ to λ light chains (i.e., outside the range of 0.26 to 1.65 for normal kidney function and 0.37 to 3.1 for poor kidney function) better serves to indicate a monoclonal gammopathy in patients with advanced CKD than the actual quantity of κ and λ light chains.

46
Q

Paraprotein-Related Disorders

Diagnosis

Testing options for monoclonal gammopathy:

A

NOTE: Serum-free light chain assay is particularly important in the diagnosis of nonsecretory myeloma, AL amyloidosis (patients with amyloidosis may not have active myeloma), and light-chain-only myeloma.

47
Q

Paraprotein-Related Disorders

Diagnosis

Testing options for monoclonal gammopathy:

A

Evaluation of suspected monoclonal gammopathy (International Myeloma Working Group):

  1. Serum protein electrophoresis with immunofixation
  2. 24-hour urine protein electrophoresis
  3. Serum FLC
48
Q

Paraprotein-Related Disorders

Histopathology

Amyloidosis

A

LM: Amyloid stains as silver and PAS negative material in mesangial regions and/or capillary walls. It is Congo red positive and displays apple green birefringence when viewed with polarized light

49
Q

Paraprotein-Related Disorders

Histopathology

Amyloidosis

A

IF: Smudgy amorphous staining for the appropriate light and/or heavy chain. If it is a non-AL amyloid (AA amyloid, transthyretin, Lect2, fibrinogen Aα), there is no light chain or immunoglobulin staining.

50
Q

Paraprotein-Related Disorders

Histopathology

Amyloidosis

A

EM: 10 nm haphazardly arranged fibrils.

51
Q

Paraprotein-Related Disorders

Histopathology

Monoclonal immunoglobulin deposition disease (MIDD)

A

LM: Glomeruli may appear nodular identical to diabetic glomerulosclerosis, mesangial proliferative, crescentic or normal

52
Q

Paraprotein-Related Disorders

Histopathology

Monoclonal immunoglobulin deposition disease (MIDD)

A

IF: Diffuse strong linear staining of all renal basement membrane and extracellular material for the abnormal light and/or heavy chain.

53
Q

Paraprotein-Related Disorders

Histopathology

Monoclonal immunoglobulin deposition disease (MIDD)

A

EM: Coarse granular electron dense material along/within glomerular and tubular basement membranes.

54
Q

Paraprotein-Related Disorders

Management
Volume repletion with normal saline is key.

Management of hypercalcemia:

A

Administration of normal saline as safely tolerated

55
Q

Paraprotein-Related Disorders

Management
Volume repletion with normal saline is key.

Management of hypercalcemia:

A

Corticosteroids ± bisphosphonates (pamidronate > zolendronate (due to dosing problem with severe kidney failure in the latter; calcitonin if refractory to bisphosphonates or rapid calcium reduction is needed).

56
Q

Paraprotein-Related Disorders

Management

Volume repletion with normal saline is key.

Management of hypercalcemia:

A

Hemodialysis if severe hypercalcemia (serum calcium > 18 mg/dL)

57
Q

Paraprotein-Related Disorders

Management

A

Avoid contrast studies, NSAIDS, nephrotoxic medications

58
Q

Paraprotein-Related Disorders

Management

Chemotherapy for underlying multiple myeloma, common regimens:

A

Bortezomib (Velcade, proteasome inhibitor) + CYC + dexamethasone

Bortezomib + melphalan + prednisone

59
Q

Paraprotein-Related Disorders

Management

Chemotherapy for underlying multiple myeloma, common regimens:

A

Lenalidomide (Revlimid) + dexamethasone

Melphalan + prednisone + thalidomide

60
Q

Paraprotein-Related Disorders

Management

Chemotherapy for underlying multiple myeloma, common regimens:

A

Thalidomide + dexamethasone

Bortezomid + lenalidomide + dexamethasone

61
Q

Paraprotein-Related Disorders

Management

Chemotherapy for underlying multiple myeloma, common regimens:

A

Reduction of serum FLC with chemotherapy predicts renal response in multiple myeloma. Plasma exchange has not been shown to improve kidney function in MM.

62
Q

Paraprotein-Related Disorders

Management

Treatment of AL amyloidosis:

Nonmyeloablative chemotherapy and autologous stem cell transplantation (ASCT)

A

Preferred therapy, but high risk of serious complications

63
Q

Paraprotein-Related Disorders

Management

Treatment of AL amyloidosis:

Nonmyeloablative chemotherapy and autologous stem cell transplantation (ASCT)

A

Criteria of eligibility for ASCT: NT-probrain natriuretic peptide < 5,000 ng/mL, troponin T < 0.06 ng/mL, age < 70 years, <3 organs involved, SCr < 1.7 mg/dL

64
Q

Paraprotein-Related Disorders

Management

Treatment of AL amyloidosis:

Triple therapy if cannot tolerate ASCT:

A

CYC + thalidomide (or lenalidomide or bortezomib) + dexamethasone

Melphalan + lenalidomide + prednisone

65
Q

Paraprotein-Related Disorders

Management

Treatment of AL amyloidosis:

Triple therapy if cannot tolerate ASCT:

A

Double therapy if cannot tolerate triple therapy: oral melphalan and dexamethasone

66
Q

Paraprotein-Related Disorders

Management

Treatment of AL amyloidosis:

A

Dialysis support as necessary

Plasmapheresis in the presence of hyperviscosity

67
Q

Paraprotein-Related Disorders

Other Fibrillary Disorders

A

Fibronectin GN: autosomal-dominant disorder associated with massive deposition of fibronectin.

68
Q

Paraprotein-Related Disorders

Other Fibrillary Disorders

A

Collagenofibrotic (collagen III) GN: GN associated with massive accumulation of atypical type III collagen fibrils in mesangium and subendothelial space

69
Q

Paraprotein-Related Disorders

Other Fibrillary Disorders

A

Nail–patella syndrome and hereditary multiple exostoses syndrome (or hereditary multiple osteochondromas syndrome) with nephrotic syndrome and associated glomerular fibrillar collagen deposition

Nephrology Boards: Glomerular Diseases (23 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions